Scientific insights: The Integrin α4β7 landscape in IBD
Eli Lilly’s $3.2B acquisition of Morphic put renewed focus on Integrin α4β7 as a target in IBD. In collaboration with Sleuth, we assessed the competitive landscape and key risks for MORF-057—including its differentiation potential as a gut-selective oral therapy.